Team members involved:

Team members involved:

Glenside provides specialist assessment, treatment and rehabilitation for adults with acute or long-term neurological conditions, including traumatic brain injury, through a complete range of rehabilitation services. It operates from two sites in the South of England and has an outstanding reputation for the high quality of its care.

  • Investment: February 2011
  • Sector: Healthcare
  • Business: Neuro-rehabilitation services
  • Growth Strategy: Roll-out

Why we invested

Glenside is a leading operator in a specialised, and increasingly important, sector of the healthcare industry. The company provides a unique care pathway for people with an acquired brain injury, providing rehabilitation and support to help them return to the most independent lifestyle possible, and has an excellent track record of positive patient outcomes. This was an opportunity to back the company’s strategy to roll-out purpose-built care homes in the South of England, where there is significant demand for its specialist services.

The result

During Bowmark’s period of investment, Glenside expanded the scale and scope of its services, including opening a new specialist 22-bed care home in Farnborough and redeveloping the company’s main site in Salisbury, which significantly improved the quality of the facilities and enlarged its capacity.  In addition, Glenside further enhanced its reputation as a high quality provider of specialist care, achieving a “good with outstanding features” rating from the Care Quality Commission in 2016.  In 2017, Glenside was sold to Raphael Medical Centre for an undisclosed sum.

Website: Read more about our Healthcare strategy

With Bowmark’s support, we have successfully grown the business while achieving the highest standards of care, and continued to deliver exceptional outcomes for our service users.

Christina Walsh, Chief Executive
Back to portfolio